Description

AOD-9604 Peptide

(Anti-Obesity Drug 9604)

What Is AOD-9604?

AOD-9604 is a synthetic peptide fragment derived from the C-terminal region of human growth hormone (hGH), specifically amino acids 176-191 of the GH molecule. It was originally developed by Metabolic Pharmaceuticals in Australia as part of research into treatments for obesity and metabolic dysfunction.

Unlike full growth hormone or other GH-related peptides, AOD-9604 was engineered to retain the fat-metabolism effects of GH while eliminating the growth-promoting and insulin-altering properties associated with the hormone.

Because of this targeted design, AOD-9604 is studied as a selective metabolic peptide that influences lipid metabolism without affecting IGF-1 levels or general endocrine balance.

What Does AOD-9604 Do?

AOD-9604 is best known for its potential role in fat metabolism and metabolic regulation. Research has examined its ability to:

• Stimulate lipolysis (fat breakdown)
• Inhibit lipogenesis (fat storage)
• Improve metabolic efficiency in adipose tissue
• Support healthy body composition

Unlike stimulants or appetite suppressants, AOD-9604 acts primarily at the cellular level of fat metabolism rather than through central nervous system pathways.

How Does AOD-9604 Function in the Body?

AOD-9604 works through several metabolic signaling pathways related to fat metabolism and adipocyte regulation.

1. Activation of Fat Breakdown (Lipolysis)

AOD-9604 stimulates enzymes involved in breaking down stored triglycerides in adipose tissue, leading to increased release of free fatty acids for energy use.

2. Inhibition of Fat Formation (Lipogenesis)

The peptide appears to suppress pathways responsible for new fat cell formation and lipid accumulation, helping shift metabolism toward fat utilization rather than storage.

3. Targeted GH Fragment Activity

Although derived from growth hormone, AOD-9604 does not stimulate the pituitary gland or increase IGF-1 levels. Instead, it isolates the metabolic component of GH signaling responsible for lipid metabolism regulation.

4. Adipocyte Signaling Regulation

Research suggests AOD-9604 may influence cellular signaling within adipose tissue, helping regulate the balance between energy storage and energy mobilization.

What Do Studies Show?

Research involving AOD-9604 has demonstrated several metabolic effects:

• Increased fat metabolism in animal and human metabolic studies
• Reduction in adipose tissue accumulation in experimental models
• No significant impact on blood glucose, IGF-1, or insulin levels
• Favorable safety and tolerability in clinical trials

Several clinical studies evaluating AOD-9604 for obesity showed good safety profiles, though results regarding weight loss efficacy were mixed depending on study design and dosing.

The peptide continues to be studied for metabolic optimization and body composition research.

Overall Benefits of AOD-9604

• Supports fat metabolism and lipid mobilization
• Inhibits new fat storage pathways
• Targets adipose tissue without stimulating growth hormone activity
• Does not elevate IGF-1 levels
• Favorable tolerability profile in research settings

AOD-9604 is often positioned as a metabolic support peptide, commonly discussed alongside GLP-1–based peptides, MOTS-c, or GH-axis peptides in metabolic and body composition research frameworks.

Important Regulatory Note

AOD-9604 is not FDA-approved for medical use in the United States and is sold as a research peptide only. This information is provided for educational and informational purposes and is not intended to diagnose, treat, cure, or prevent any disease.

Key Studies Supporting AOD-9604 Research

1. Lipolysis and Fat Metabolism Mechanism Study

The Effects of Human GH and Its Lipolytic Fragment (AOD9604) on Lipid Metabolism
🔗 https://pubmed.ncbi.nlm.nih.gov/11713213/

Key Findings

• AOD-9604 increased lipolysis and fat oxidation in obese animal models.

• Treatment reduced body weight and body fat accumulation.

• Mechanistic work suggested involvement of β3-adrenergic pathways related to fat metabolism.

Why it matters:
This study provides foundational evidence that the GH fragment responsible for fat metabolism can function independently of full growth hormone activity.

2. Metabolic Effects and Insulin Safety Study

Metabolic Studies of a Synthetic Lipolytic Domain of Human Growth Hormone (AOD9604)
🔗 https://pubmed.ncbi.nlm.nih.gov/11146367/

Key Findings

• AOD-9604 increased fat oxidation and lipolysis in obese mice.

• Reduced body-weight gain during treatment.

• Unlike full growth hormone, it did not impair insulin sensitivity or glucose regulation.

Why it matters:
This research supports the claim that AOD-9604 retains fat-metabolism effects without GH-related endocrine side effects.

3. Clinical Safety and Tolerability Study

Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans
🔗 https://www.jofem.org/index.php/jofem/article/view/157/194

Key Findings

• Analysis of six randomized, double-blind clinical trials.

• AOD-9604 showed a strong safety profile and good tolerability in humans.

• Designed to preserve the fat-reducing properties of GH while avoiding its adverse effects.

Why it matters:
Provides the best clinical safety data available for AOD-9604.

4. Review of Anti-Obesity Pharmacology

Obesity Pharmacotherapy: Current Perspectives and Future Directions
🔗 https://pmc.ncbi.nlm.nih.gov/articles/PMC3584306/

Key Findings

• AOD-9604 is described as a GH fragment analogue that selectively activates lipolysis in adipose tissue.

• Demonstrated fat-reducing activity in experimental obesity models without typical GH metabolic side effects.

Why it matters:
Provides independent confirmation in a peer-reviewed metabolic pharmacology review.